The inhibitory effects of vasodilator, Bencyclane [N-(3-(1-benzyl-cycloheptyl-oxy)-propyl)-N, N-dimethyl-ammonium hydrogen fumarate] on platelet function in rabbits were investigated in vitro and in vivo.
In studying in vitro, Bencyclane inhibits platelet retention by concentration of 10^-5M (final conc., P<0.01).
ADP-induced platelet aggregation was slightly depressed by Bencyclane in the concentration-range of 10^-5M-10^-4M, however, concentration of 1.25×10^-4M significantly ieduced to 50% of initial aggregation rate (p<0.025).
Inhibition rates of collagen-induced platelet aggregation were 35% and 51% at the concentration of 10^-6M, 10^-5M (p<0.025), respectively.
On the other hand, in vivo studying, intravenous administration of Bencyclane in the dose of 0.4mg/kg body weight causes the depression of platelet retention, and these rates were 35.6%, 39.8%, 30.0% after injection 1, 6 and 24 hours, individually.
The dose of 4mg/kg i. v. shows the inhibition of platelet retention, its rates were 66.1% (p<0.005), 43.7% (p<0.01), 19.1% after administration 1, 6, 24 hours, respectively.
ADP-induced platelet aggregation was supressed to 63.2% (p<0.025), 38.1%-10.5% by the dose of 0.4mg/kg after intravenous injection 1, 6, 24 hours, and the dose of 4mg/kg i. v. was more effective, these values were 73.7% (p<0.025), 49.0% (p<0.05), -2.9% after injection 1, 6, 24 hours, indvidually.
These results indicate that the addition of Bencyclane in concentration of 10^-5M (final cone.) inhibits retention and aggregation of rabbit platelet.

View full abstract